To reinvigorate the immune system to fight tumour cells, the PD-1/PD-L1 interaction could be considered a potential target for some monoclonal antibodies (mAbs), resulting in the inhibition of this interaction [103]. The gene discussed is CD274; the disease is neoplasm.